Lansoprazole-induced microscopic colitis: An increasing problem? Results of a prospecive case-series and systematic review of the literature

Digestive and Liver Disease

Volumn 43, Issue 5, 2011, Pages 380-385

  Capurso, Gabriele ^a   Marignani, Massimo ^a   Attilia, Fabio ^a   Milione, Massimo ^a   Colarossi, Cristina ^a   Zampaletta, Costantino ^b   Di Giulio, Emilio ^a   Delle Fave, Gianfranco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BELCOLLE HOSPITAL   (Italy)

Author keywords

Collagenous colitis; Lansoprazole; Lymphocytic colitis; Microscopic colitis

Indexed keywords

ACETYLSALICYLIC ACID; ALFUZOSIN; ATENOLOL; DOXAZOSIN; DUTASTERIDE; ESOMEPRAZOLE; GLIBENCLAMIDE; ISOSORBIDE; LANSOPRAZOLE; LOPERAMIDE; METFORMIN; METHOTREXATE; METHYLPREDNISOLONE; NIMESULIDE; OMEPRAZOLE; PANTOPRAZOLE; RIFAXIMIN; SIMVASTATIN; TICLOPIDINE;

AGED; ARTICLE; CLINICAL ARTICLE; COLITIS; COLONOSCOPY; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HISTOLOGY; HUMAN; MALE; MEDLINE; MICROSCOPIC COLITIS; MICROSCOPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ABDOMINAL PAIN; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; COLITIS, COLLAGENOUS; COLITIS, LYMPHOCYTIC; DIARRHEA; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 79953278141     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.11.015     Document Type: Article

References (24)

1. Zins B.J., Sandborn W.J., Tremaine W.J. Collagenous and lymphocytic colitis: subject review and therapeutic alternatives. Am J Gastroenterol 1995, 90:1394-1400.
2. Nyhlin N., Bohr J., Eriksonn S., et al. Systematic review: microscopic colitis. Aliment Pharmacol Ther 2006, 23:1525-1534.
3. Olsen M., Eriksson S., Bohr J., et al. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 2004, 53:346-350.
4. Pardi D.S., Loftus E.V., Smyrk T.C., et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut 2007, 56:504-508.
5. Williams J.J., Kaplan G.G., Makhija S., et al. Microscopic colitis-defining incidence rates and risk factors: a population-based study. Clin Gastroenterol Hepatol 2008, 6:35-40.
6. Cappel M.S. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004, 99(6):1175-1190.
7. Beaugerie L., Pardi D.S. Review article: drug-induced microscopic colitis-proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 2005, 22:277-284.
8. Martin R.M., Dunn R.D., Freemantle S., et al. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000, 50:366-372.
9. Freston J.W., Hisada M., Peura D.A., et al. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2009 June 15, 29(12):1249-1260.
10. Thomson R.D., Lestina L.S., Bensen S.P., et al. Lansoprazole-associated microscopic colitis: a case series. Am J Gastroenterol 2002, 97:2908-2913.
11. Wilcox G.M., Mattia A. Collagenous colitis associated with lansoprazole. J Clin Gastroenterol 2002, 34:164-166.
12. Mukherjee S. Diarrhea associated with lansoprazole. J Gastroenterol Hepatol 2003, 18:602-603.
13. Hilmer S.H., Heap T.R., Eckstein R.P., et al. Microscopic colitis associated with exposure to lansoprazole. MJA 2006, 184:185-186.
14. Chande N., Driman D.K. Microscopic colitis associated with lansoprazole: report of two cases and a review of the letteratute. Scand J Gastroenterol 2007, 42:530-533.
15. Umeno J., Matsumoto T., Nakamura S., et al. Linear mucosal defect may be characteristic of lansoprazole-associated collagenous colitis. Gastrointest Endosc 2008, 67:1185-1191.
16. Yusuke H., Jun T., Naotaka M., et al. Lansoprazole-associated collagenous colitis: unique presentation, similar to ischemic colitis. Endoscopy 2009, 41(2):E281-282.
17. Chiba M., Sugawara T., Tozawa H., et al. Lansoprazole-associated collagenous colitis: diffuse mucosal cloudiness mimicking ulcerative colitis. World J Gastroenterol 2009, 15:2166-2169.
18. Nomura E., Kagaya H., Uchimi K., et al. Linear mucosal defects: a characteristic endoscopic finding of lnsoprazole-associated collagenous colitis. Endoscopy 2010, 42(2):E9-10.
19. Sveinsson O.A., Orvar K.B., Birgisson S., et al. Clinical features of microscopic colitis in a nation-wide follow-up study in Iceland. Scand J Gastroenterol 2008, 43:955-960.
20. Wickbom A., Lindqvist M., Bohr J., et al. Colonic mucosal tears in collagenous colitis. Scand J Gastroenterol 2006, 41:726-729.
21. Nakamura M., Matsui H., Serizawa H., et al. Lansoprazole novel effector sites revealed by autoradiography: relation to helicobacter pylori, colon, esophagus and others. J Clin Biochem Nutr 2007, 41:154-159.
22. Wilcox G.M., Mattia A.R. Microscopic colitis associated with omeprazole and esomeprazole exposure. J Clin Gastroenterol 2009, 43:551-553.
23. http://www.fog.it/fogliani/giancarlo/DGR%20124%20del%2027-2-07.pdf.
24. Skinner B.J., Gray J.R., Attara G.P. Increased health costs from mandated therapeutic substitution of proton pump inhibitors in British Columbia. Aliment Pharmacol Ther 2009, 29:882-891.